SACHS Biocapital USA Forum taking place on 21st March at the New York Academy of Sciences, USA. We are delighted to announce that CEO Lynn Durham will deliver a presentation showcasing STALICLA’s innovative approach and development pipeline, at 11:20am. In addition, Lynn will also be a part of the of the ‘Renewed Approaches for Neuroscience’ panel, which will be held at 11:45am. The Plenary panel is likely to be a highly anticipated session where Lynn will be discussing the hot topic of advanced therapeutics alongside other biotech and pharmaceutical leaders.
STALICLA selected among the 2018 top 50 start-ups in Switzerland.
STALICLA announced today that Lynn Durham, CEO and Founder, is scheduled to present at the 11th SACHS Associates 11th Annual Life Sciences CEO Forum being held February 26-27 in Zurich, Switzerland.
STALICLA is proud to announce its selection on JPM UK Private Bank start-up ticket. Lynn Durham, CEO and Founder, is scheduled to present to the Healthcare Executive team during the 36th Annual JPM Healthcare conference, being held January 8-11, 2018 in San Francisco. Lynn’s presentation on the company’s strategy and development pipeline will take place on Tuesday 9th of January 2018 at 14:00 pm EST, 6th floor Westin St-Francis room.
STALICLA is excited to announce a long-term research partnership with the Greenwood Genetic Center (GGC), a leading translational research center for neurodevelopmental disorders, including autism spectrum disorder (ASD).